[Botulinum toxin type A for the treatment of spasticity in children with cerebral palsy].

BACKGROUND/AIM Cerebral palsy (CP) is the most common physical disability in childhood. Children have problems with motor functions as a result of limbs spasticity, which leads to severe contractures and limbs deformity. There is a growing interest in the therapeutic role of botulinum toxin type A (BTA) in CP. The aim of this study was to examine the effects of BTA on spasticity, active range of motion and functional motor outcomes in children with CP. METHODS This study included 42 children of both sexes, aged 2-6 years, with spastic CP, divided into two groups: group I (21 child) treated with BTA and physical therapy, and group II (21 child) treated with physical therapy only. The following parameters were analyzed: spasticity; active range of motion of the hip, knee and ankle, and functional motor outcome. These parameters measurements were carried out four times in both groups: before the treatment, three, eight and 16 weeks after the beginning of the treatment. The obtained results were statistically processed and compared. RESULTS There was no evidence of any significant difference between the groups before the treatment. After eight weeks there was a remarkable difference concerning spasticity reducing on behalf of the group I (group I -- 0.76 +/- 0.51 vs. II group -- 2.17 +/- 0.64; p < 0.0001). There was statistically significant difference concerning active range of motion increasing on behalf of the group I (hip abduction: group I --44.37 +/- 1.13(0) vs. group II -- 32.61 +/- 8.07(0),p < 0,01; knee extension: group I -- 0.77 +/- 1.82(0) vs. II group -- 14.99 +/- 7.61(0), p < 0.01; dorsiflexion of the foot: group I -- 11.50 +/- 6.08(0) vs. group II -- 8.98 +/- 7.85(0), p < 0.01). A statistically significant difference was found after 16 weeks in functional motor outcome as well, on behalf of the group I: functional motor abilities level in the group I was 1.86 vs. 2.71 in the group II, p < 0.05. CONCLUSION Botulinum toxin type A application leads to an important spasticity decreasing, active range of motion increasing, as well as to functional abilities in children with CP.

[1]  G. Molenaers,et al.  Safety and efficacy of botulinum toxin type A following long‐term use , 2006, European journal of neurology.

[2]  R. Tervo,et al.  Parent evaluation of spasticity treatment in cerebral palsy using botulinum toxin type A. , 2006, Archives of physical medicine and rehabilitation.

[3]  J. Dolly,et al.  The structure and mode of action of different botulinum toxins , 2006, European journal of neurology.

[4]  D. Knol,et al.  The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. , 2006, Archives of physical medicine and rehabilitation.

[5]  A. Berardelli,et al.  Clinical value of botulinum toxin in neurological indications , 2006, European journal of neurology.

[6]  D. Patel,et al.  Pharmacologic interventions for reducing spasticity in cerebral palsy , 2005, Indian journal of pediatrics.

[7]  I. Autti-Rämö,et al.  Botulinum Toxin Treatment of Spastic Equinus in Cerebral Palsy: A Randomized Trial Comparing Two Injection Sites , 2005, American journal of physical medicine & rehabilitation.

[8]  G. Lankhorst,et al.  The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling , 2005, Clinical rehabilitation.

[9]  F. Pidcock,et al.  Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A. , 2005, Archives of physical medicine and rehabilitation.

[10]  P. Singhi,et al.  Botulinum toxin in children with cerebral palsy , 2004, Indian journal of pediatrics.

[11]  G. Serdaroğlu,et al.  The use of botulinum toxin type A treatment in children with spasticity. , 2003, Pediatric neurology.

[12]  P. Rosenbaum.  Cerebral palsy: what parents and doctors want to know , 2003, BMJ : British Medical Journal.

[13]  V. Wong.  Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy , 2003, Pediatric rehabilitation.

[14]  P. Flett.  Rehabilitation of spasticity and related problems in childhood cerebral palsy , 2003, Journal of paediatrics and child health.

[15]  R. Morton,et al.  The role of botulinum toxin in the management of cerebral palsy , 2001 .

[16]  F. Heinen,et al.  Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option , 2001, Journal of Neurology.

[17]  A. Cosgrove,et al.  Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. , 2001 .

[18]  P. Raina,et al.  Validation of a model of gross motor function for children with cerebral palsy. , 2000, Physical therapy.

[19]  E. Wood,et al.  The Gross Motor Function Classification System for Cerebral Palsy: a study of reliability and stability over time , 2000, Developmental medicine and child neurology.

[20]  N. Gordon.  The role of botulinus toxin type A in treatment – with special reference to children , 1999, Brain and Development.

[21]  V. Wong,et al.  Use of botulinum toxin injection in 17 children with spastic cerebral palsy. , 1998, Pediatric neurology.

[22]  D. Knol,et al.  Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy. , 2007, Pediatric neurology.

[23]  W. Bandy,et al.  Serial Casting vs Combined Intervention with Botulinum Toxin A and Serial Casting in the Treatment of Spastic Equinus in Children , 2003, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[24]  H. Dumas,et al.  Physical Therapy Intervention for Children with Cerebral Palsy Who Receive Botulinum Toxin A Injections , 2003, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[25]  H. Dumas,et al.  Impairment, Disability, and Satisfaction Outcomes After Lower‐Extremity Botulinum Toxin A Injections for Children with Cerebral Palsy , 2002, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[26]  M E Gormley,et al.  Treatment of neuromuscular and musculoskeletal problems in cerebral palsy. , 2001, Pediatric rehabilitation.

[27]  H. Dumas,et al.  Expert Consensus on Physical Therapist Intervention after Botulinum Toxin A Injection for Children with Cerebral Palsy , 2001, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.